poisar

Stocks · News reference

B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk

B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

UNCY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Robbins Llp

    UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

    A class action lawsuit was filed against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility before resubmitting a New Drug Application to the FDA. The company's stock dropped 39.1% on June 30, 2026, when the FDA issued a Complete Response Letter citing the same manufacturing deficiencies previously identified. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible to participate in the lawsuit.

    UNCY